TY - JOUR
T1 - State-of-the-art methods in clinical intracochlear drug delivery
AU - Chin, Oliver Y.
AU - Diaz, Rodney C
PY - 2019/10/1
Y1 - 2019/10/1
N2 - Purpose of reviewIncreasing awareness and prevalence of disorders in hearing and balance have placed emphasis on treatment strategies. With the rapid evolution in molecular, gene, and nanotechnology, alternate delivery methods have advanced intracochlear drug delivery. This review aims to raise awareness of recent developments in technologies to augment current clinical practices.Recent findingsIntracochlear drug delivery research has expanded with the familiarity and accessibility to cochlear implantation. Various therapeutics are closely studied for both safety and efficacy as well as biologic effect. Agents including neurotrophins, antiapoptotics, cell therapy, gene therapy, and anti-inflammatory drugs are on the forefront of preclinical research. Cochlear implant electrode modification and drug administration at the time of implantation is a major focus of research. Improvements in study design have focused on overcoming barriers including elucidating the role of the blood-perilymph barrier.SummaryInner ear drug delivery methods include systemic, intratympanic, and intracochlear administration. Therapeutic technologies aim to overcome delivery barriers and to improve overall biologic effect while minimizing toxicity. Precision of drug application through intratympanic and intracochlear administration with minimal trauma is the future of inner ear drug development.
AB - Purpose of reviewIncreasing awareness and prevalence of disorders in hearing and balance have placed emphasis on treatment strategies. With the rapid evolution in molecular, gene, and nanotechnology, alternate delivery methods have advanced intracochlear drug delivery. This review aims to raise awareness of recent developments in technologies to augment current clinical practices.Recent findingsIntracochlear drug delivery research has expanded with the familiarity and accessibility to cochlear implantation. Various therapeutics are closely studied for both safety and efficacy as well as biologic effect. Agents including neurotrophins, antiapoptotics, cell therapy, gene therapy, and anti-inflammatory drugs are on the forefront of preclinical research. Cochlear implant electrode modification and drug administration at the time of implantation is a major focus of research. Improvements in study design have focused on overcoming barriers including elucidating the role of the blood-perilymph barrier.SummaryInner ear drug delivery methods include systemic, intratympanic, and intracochlear administration. Therapeutic technologies aim to overcome delivery barriers and to improve overall biologic effect while minimizing toxicity. Precision of drug application through intratympanic and intracochlear administration with minimal trauma is the future of inner ear drug development.
KW - direct intracochlear drug
KW - indirect intracochlear drug
KW - inner ear drug
KW - otic drug
UR - http://www.scopus.com/inward/record.url?scp=85071468970&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85071468970&partnerID=8YFLogxK
U2 - 10.1097/MOO.0000000000000566
DO - 10.1097/MOO.0000000000000566
M3 - Review article
C2 - 31460985
AN - SCOPUS:85071468970
VL - 27
SP - 381
EP - 386
JO - Current Opinion in Otolaryngology and Head and Neck Surgery
JF - Current Opinion in Otolaryngology and Head and Neck Surgery
SN - 1068-9508
IS - 5
ER -